SCHEMBL4751241

SCHEMBL4751241

Nc1ncnc2c(CN3CC(O)[C@@H](CO)C3)n[nH]c12

nearest known ligand 0.55

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MTAP Q13126 14/20 0.55
PNP P00491 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4736664 1.00 MTAP (0.55) MTAPPNP
SCHEMBL30583179 0.81 MTAP (0.81) MTAPPNP
SCHEMBL4736669 0.81 MTAP (0.81) MTAPPNP
SCHEMBL12373430 0.81 MTAP (0.81) MTAPPNP
SCHEMBL4736878 0.81 MTAP (0.74) MTAP
SCHEMBL12715892 0.81 MTAP (0.74) MTAP
SCHEMBL4736658 0.79 PNP (0.67) PNP
SCHEMBL4751244 0.79 PNP (0.67) PNP
SCHEMBL13813963 0.79 MTAP (0.41) MTAPPNP
SCHEMBL13201649 0.77 MTAP (0.43) MTAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173662-B2 Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases INDUSTRIAL RESEARCH LIMITED (NZ) 2012-05-08 US disclosed
EP-1539783-B1 INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES EINSTEIN COLL MED (US) 2011-04-13 EP disclosed
US-20090239885-A1 Inhibitors of nucleoside phoshorylases and nucleosidases BIOCRYST PHARMACEUTICALS, INC. 2009-09-24 US disclosed
US-7553839-B2 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases INDUSTRIAL RESEARCH LIMITED (NZ) 2009-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239885-A1 Inhibitors of nucleoside phoshorylases and nucleosidases PNP, MTAP, TYMP MTAP 2/4885PNP 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.